Lancet HIV recognises Transgender Day of Visibility and the importance of gender-affirming hormones in HIV care
3 April 2025. Related: Journal scan, Special reports, Treatment access.
2025
CROI 2025: BHIVA best of CROI feedback now online
1 April 2025. Related: Conference reports, On the web.
People living with HIV need two shots of the mpox vaccine and likely a booster after two years
1 April 2025. Related: Journal scan, mpox.
CROI 2025: Two bNAbs enable viral suppression off-ART in African women in the FRESH cohort
1 April 2025. Related: Conference reports, Cure-related research.
Cuts in aid: up to 10 million new HIV infections and almost 3 million related deaths by 2030
28 March 2025. Related: Journal scan, Treatment access.
Stopping ART safely if your clinic is closed or runs out of meds: a practical guide
25 March 2025. Related: Special reports, Treatment strategies.
Webinar on stopping ART if your clinic is closed: practical facts on safety and risk
24 March 2025. Related: Special reports, Treatment strategies, Treatment access, On the web.
CROI 2025: Introduction to this year’s conference
22 March 2025. Related: Conference reports.
CROI 2025: RIO study: Dual-bNABs keep viral load undetectable off-ART – plus a potential first case of vaccine-like HIV remission
21 March 2025. Related: Conference reports, Cure-related research.
CROI 2025: Switching to daily fixed-dose doravirine/islatravir: two randomised phase 3 studies
20 March 2025. Related: Conference reports, Antiretrovirals.
CROI 2025: Tecovirimat has no benefit against mpox in STOMP study
18 March 2025. Related: Conference reports, mpox.
CROI 2025: Ensitrelvir significantly reduces risk of developing COVID-19 after household exposure
18 March 2025. Related: Conference reports, COVID-19.
CROI 2025: N6LS: 4-monthly injectable bNAb with monthly injectable cabotegravir
18 March 2025. Related: Conference reports, Antiretrovirals.
Summary of Australian guidelines for anal cancer screening in people living with HIV
18 March 2025. Related: Guidelines.
CROI 2025: Reducing Biktarvy from daily to only once, twice or three times a week
17 March 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.
CROI 2025: Potential for once-yearly lenacapavir injections
16 March 2025. Related: Conference reports, Antiretrovirals, PK and drug interactions, HIV prevention and transmission.
CROI 2025: Delegates send open letter to protest US cuts
12 March 2025. Related: Conference reports, Activism & advocacy.
CROI 2025: Stand Up For Science rally against Trump funding freeze
9 March 2025. Related: Conference reports, Activism & advocacy.
HIV and vaccine denialist is proposed to head the US NIH: further alarm for global science
7 March 2025. Related: Activism & advocacy.
Global update: 90-day review ended early and cancelled 10,000 grants, millions of people will suffer
1 March 2025. Related: Special reports, Treatment access.
Responses to the UK government slashing international aid by 40%
26 February 2025. Related: Treatment access, Activism & advocacy.
Deleted words from official documents: LGBTQ, diversity, inclusion, transgender
26 February 2025. Related: Treatment access, Activism & advocacy.
Country update from Nigeria: current impact on HIV services
22 February 2025. Related: Special reports, Treatment access.
Semaglutide reduces alcohol and cigarette use in a randomised phase 2 study
12 February 2025. Related: Weight, diabetes, metabolic complications, Coinfections and complications.
News and resources linked to changes in US policy on international aid
7 February 2025. Related: Special reports.
Impact of US elections and executive orders on global health: waiver covers PEPFAR with restrictions
7 February 2025. Related: Special reports, Treatment access, Activism & advocacy.
IAS public letter: Why HIV could be poised for a monumental comeback
6 February 2025. Related: Treatment access, On the web.
Lenacapavir for PrEP submitted to EMA for EU and global use
4 February 2025. Related: Antiretrovirals, HIV prevention and transmission.
New mpox vaccination sites open in the UK
3 February 2025. Related: mpox.
Africa CDC special briefing on mpox and the impact of conflict
1 February 2025. Related: mpox.
EU license for injectable cabotegravir/rilpivirine injections expanded to include adolescents >12 years old
31 January 2025. Related: Antiretrovirals.
US issues temporary waiver to re-enable PEPFAR
29 January 2025. Related: Treatment access.
IAS statement: PEPFAR freeze threatens millions of lives
25 January 2025. Related: Treatment access.
Trump bans travel for US government scientists, presentations restricted, language bans, documents disappearing
23 January 2025. Related: Treatment access, Activism & advocacy, Research studies.
Almost 1 in 5 people in Switzerland disconnected from HIV care over 10 years: only half reconnected and with advanced infection
22 January 2025. Related: Special reports, Treatment strategies.
BHIVA pregnancy guidelines online for comment: deadline 25 January
20 January 2025. Related: Pregnancy, Guidelines.
Detailed results from PALM007 study: no clinical impact of tecovirimat against mpox clade 1
6 January 2025. Related: mpox.
Tecovirimat news continues: Japan approval includes mpox indication
2 January 2025. Related: mpox.
Looking back through 2024 and forward to 2025…
1 January 2025. Related: Editorial, Special reports.
i-Base appeal: Q&A services and the website in 2025
1 January 2025. Related: Editorial, Special reports.
ART pipeline 2025: exciting dual long-acting combinations and the challenge of generic dolutegravir
1 January 2025. Related: Special reports, Conference reports, Pipeline report, Antiretrovirals.
Transient impact of lenacapavir against MDR HIV-2 without other active ART
1 January 2025. Related: Antiretrovirals, Treatment strategies, Virology, Drug resistance.
Lenacapavir submitted to the US FDA with an indication for HIV PrEP
1 January 2025. Related: Antiretrovirals, Treatment access, HIV prevention and transmission.